News Releases

Hiccups relief tool

Team describes science-based hiccups intervention

June 18, 2021

Users reported relief in 92% of cases. Contact: Will Sansom, 210-567-2579, SAN ANTONIO (June 18, 2021) — Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and colleagues worldwide describe a new science-based intervention for hiccups in a research letter published June 18 in the journal JAMA […]

In JAMA Oncology: Convalescent plasma improves survival in COVID-19 patients with blood cancers

June 17, 2021

(Editor’s note: This story, originally posted on Feb. 11, 2021, has been updated to include the study’s publication in JAMA Oncology on June 17, 2021.) Contact: Will Sansom, 210-567-2579, SAN ANTONIO (June 17, 2021) — Convalescent plasma therapy was associated with better survival in blood cancer patients hospitalized with COVID-19, especially in sicker patients. […]

man with clinical depression

Depression, tau deposits seen in subset of middle-aged persons

June 17, 2021

Framingham Heart Study analysis finds association in APOE ε4 allele carriers. Contact: Will Sansom, 210-567-2579, SAN ANTONIO (June 17, 2021) — Middle-aged people with depressive symptoms who carry a genetic variation called apolipoprotein (APOE) ε4 may be more at risk to develop tau protein accumulations in the brain’s emotion- and memory-controlling regions, a new […]

Novavax vaccine is highly protective against COVID-19 in Phase 3 results

June 14, 2021

Contact: Will Sansom, 210-567-2579, Elizabeth Allen, 210-358-2344, SAN ANTONIO (June 14, 2021) — Researchers at UT Health San Antonio are buoyed by today’s news that the Novavax vaccine is strongly effective against the COVID-19 virus. Biotechnology company Novavax released Phase 3 clinical trial results from 119 sites in the U.S. and Mexico this […]

Scan of brain injury

Study will compare 2 treatment strategies for severe brain injury; public comment requested

June 10, 2021

Editor’s note: This story, originally posted on June 10, 2020, is being reposted to include a link to this anonymous survey: The public comment phase leading up to the study is nearly complete, and feedback is welcomed.   SAN ANTONIO (June 10, 2021) – A study of emergency care involving victims of severe brain […]

Alzheimer's patients

Media advisory: Experts from Glenn Biggs Institute at UT Health San Antonio available to discuss new Alzheimer’s drug

June 9, 2021

The U.S. Food and Drug Administration (FDA) on Monday, June 7, approved the drug aducanumab for the treatment of Alzheimer’s disease, which affects 6.2 million Americans. Sudha Seshadri, MD, professor of neurology at UT Health San Antonio and director of the university’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, issued the following statement: “We are excited that a drug, aducanumab (Aduhelm, from Biogen), has been approved by the FDA for treatment of persons with early symptoms due to Alzheimer’s disease. This is the first new drug approved for Alzheimer’s in two decades.”